Literature DB >> 23582509

Manipulating the PD-1 pathway to improve immunity.

Alice O Kamphorst1, Rafi Ahmed.   

Abstract

PD-1 is an inhibitory receptor induced in T cells by antigen stimulation and sustained PD-1 expression plays a key role in T cell dysfunction. Blocking PD-1 signaling rescues exhausted T cells and is an effective treatment for chronic infections and cancer. Nonetheless, combining PD-1 pathway blockade to therapeutic vaccination should further improve T cell rescue. PD-1 is induced shortly after T cell priming, but little is known about the role of PD-1 in the initiation of immune responses. In addition, the PD-1 pathway may also modulate humoral responses, since both B cells and Tfh cells express PD-1. Therefore, even though much progress has been achieved by manipulation of the PD-1 pathway to rescue exhausted T cells, this powerful immunotherapy could still be further exploited.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582509      PMCID: PMC5946314          DOI: 10.1016/j.coi.2013.03.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  63 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

3.  Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.

Authors:  Janine Gotot; Catherine Gottschalk; Sonny Leopold; Percy A Knolle; Hideo Yagita; Christian Kurts; Isis Ludwig-Portugall
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

4.  The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut.

Authors:  Shimpei Kawamoto; Thinh H Tran; Mikako Maruya; Keiichiro Suzuki; Yasuko Doi; Yumi Tsutsui; Lucia M Kato; Sidonia Fagarasan
Journal:  Science       Date:  2012-04-27       Impact factor: 47.728

5.  Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells.

Authors:  Emily Hams; Mark J McCarron; Sylvie Amu; Hideo Yagita; Miyuki Azuma; Lieping Chen; Padraic G Fallon
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

6.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.

Authors:  André Ballesteros-Tato; Beatriz León; Beth A Graf; Amy Moquin; Pamela Scott Adams; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2012-03-29       Impact factor: 31.745

7.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

8.  Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Authors:  Joseph N Blattman; E John Wherry; Sang-Jun Ha; Robbert G van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

Authors:  Sabine Mumprecht; Christian Schürch; Juerg Schwaller; Max Solenthaler; Adrian F Ochsenbein
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

10.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

View more
  57 in total

1.  Bovine Immunoinhibitory Receptors Contribute to Suppression of Mycobacterium avium subsp. paratuberculosis-Specific T-Cell Responses.

Authors:  Tomohiro Okagawa; Satoru Konnai; Asami Nishimori; Ryoyo Ikebuchi; Seiko Mizorogi; Reiko Nagata; Satoko Kawaji; Shogo Tanaka; Yumiko Kagawa; Shiro Murata; Yasuyuki Mori; Kazuhiko Ohashi
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

2.  Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Authors:  Deepak A Rao; Michael F Gurish; Jennifer L Marshall; Kamil Slowikowski; Chamith Y Fonseka; Yanyan Liu; Laura T Donlin; Lauren A Henderson; Kevin Wei; Fumitaka Mizoguchi; Nikola C Teslovich; Michael E Weinblatt; Elena M Massarotti; Jonathan S Coblyn; Simon M Helfgott; Yvonne C Lee; Derrick J Todd; Vivian P Bykerk; Susan M Goodman; Alessandra B Pernis; Lionel B Ivashkiv; Elizabeth W Karlson; Peter A Nigrovic; Andrew Filer; Christopher D Buckley; James A Lederer; Soumya Raychaudhuri; Michael B Brenner
Journal:  Nature       Date:  2017-02-01       Impact factor: 49.962

3.  PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Elizabeth R Plimack; Gary R Hudes; Robert G Uzzo; Samuel Litwin; Essel Dulaimi; Tahseen Al-Saleem; Kerry S Campbell
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

4.  Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.

Authors:  Rama S Akondy; Philip L F Johnson; Helder I Nakaya; Srilatha Edupuganti; Mark J Mulligan; Benton Lawson; Joseph D Miller; Bali Pulendran; Rustom Antia; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

5.  CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.

Authors:  Xiaojuan Liu; Yongping Zhang; Chen Cheng; Albert W Cheng; Xingying Zhang; Na Li; Changqing Xia; Xiaofei Wei; Xiang Liu; Haoyi Wang
Journal:  Cell Res       Date:  2016-12-02       Impact factor: 25.617

6.  Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Authors:  Christel Devaud; Jennifer A Westwood; Michele Wl Teng; Liza B John; Carmen Sm Yong; Connie Pm Duong; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

7.  Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

Authors:  Masahiro Azuma; Yohei Takeda; Hiroko Nakajima; Haruo Sugiyama; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

Review 8.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Authors:  Manuela Terranova-Barberio; Scott Thomas; Pamela N Munster
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

9.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Authors:  Xiaojun Liu; Raghuveer Ranganathan; Shuguang Jiang; Chongyun Fang; Jing Sun; Soyeon Kim; Kheng Newick; Albert Lo; Carl H June; Yangbing Zhao; Edmund K Moon
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

10.  Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Authors:  Florin Tuluc; Sergei Spitsin; Nancy B Tustin; Jennifer B Murray; Richard Tustin; Laura A Schankel; Andrew Wiznia; Sharon Nachman; Steven D Douglas
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-18       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.